Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: IGRT 45 Gy in 5 fractions of 9 Gy
Radiation: IGRT 24 Gy single dose
Drug: Dexamethasone
Drug: Tamsulosin

First Posted Date: 2019-11-01

Last Posted Date: 2024-06-11

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 30

Registration Number: NCT04147806

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Silodosin
Drug: Tamsulosin

First Posted Date: 2019-09-27

Last Posted Date: 2019-09-27

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 141

Registration Number: NCT04107896

Locations: 🇧🇩
Maidul islam, Dhaka, Bangladesh

Prophylactic Administration of Alpha Blockers for Prevention of Urinary Retention in Males Undergoing Inguinal Hernia Repair Under Spinal Anaesthesia.

Phase 1

Completed

Conditions: Inguinal Hernia
Urinary Retention

Interventions: Drug: Placebo oral tablet
Drug: Tamsulosin

First Posted Date: 2019-06-06

Last Posted Date: 2021-11-26

Lead Sponsor: Georgios Koukoulis

Target Recruit Count: 100

Registration Number: NCT03976934

Locations: 🇬🇷
General Hospital Of Larissa, Larissa, Greece
🇬🇷
University General Hospital of Larissa, Larissa, Greece

Effect of Tamsulosin on PE Compared With Paroxetine Hydrochloride

Phase 3

Conditions: Premature Ejaculation

Interventions: Drug: Paroxetine Hydrochloride
Drug: Tamsulosin
Other: placebo

First Posted Date: 2019-03-19

Last Posted Date: 2019-03-19

Lead Sponsor: Assiut University

Target Recruit Count: 160

Registration Number: NCT03879746

Prevention of Postoperative Urinary Retention with Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty

Phase 4

Active, not recruiting

Conditions: Arthropathy of Knee
Urinary Retention Postoperative
Arthropathy of Hip

Interventions: Drug: Placebo Oral Tablet
Drug: Tamsulosin

First Posted Date: 2019-01-17

Last Posted Date: 2024-10-24

Lead Sponsor: Kantonsspital Graubünden

Target Recruit Count: 170

Registration Number: NCT03808155

Locations: 🇨🇭
Kantonsspital Graubünden, Chur, Graubünden, Switzerland

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

Phase 4

Terminated

Conditions: Lower Urinary Tract Symptoms

Interventions: Drug: Hyoscyamine
Drug: Tamsulosin

First Posted Date: 2018-11-23

Last Posted Date: 2024-12-03

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 5

Registration Number: NCT03750656

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:

Not Applicable

Suspended

Conditions: Ureter Stone
Quality of Life
Ureter Obstruction

Interventions: Drug: Trospium Chloride
Drug: Tamsulosin

First Posted Date: 2018-10-17

Last Posted Date: 2023-10-12

Lead Sponsor: Mansoura University

Target Recruit Count: 200

Registration Number: NCT03709992

Locations: 🇪🇬
Ahmed R EL-Nahas, Mansoura, Kuwait, Egypt

Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

Phase 2

Completed

Conditions: Urinary Retention
Lower Urinary Tract Symptoms
Stress Urinary Incontinence
Pelvic Organ Prolapse

Interventions: Drug: Placebo oral capsule
Drug: Tamsulosin

First Posted Date: 2018-05-14

Last Posted Date: 2021-11-08

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 132

Registration Number: NCT03524339

Locations: 🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States